Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria

Kidney International, Supplement

Volumn 66, Issue 92, 2004, Pages

  Palmer, Andrew J ^a   Rodby, Roger A ^b  

^a IQVIA   (United States)

^b NONE

Author keywords

Costs; Hypertension; Irbesartan; Microalbuminuria; Modeling; Type 2 diabetes

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; IRBESARTAN; PERIPHERAL VASODILATING AGENT; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FEMALE; HEALTH CARE COST; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MONTE CARLO METHOD; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROBABILITY; TREATMENT OUTCOME; ALBUMINURIA; ECONOMICS; RENOVASCULAR HYPERTENSION; REVIEW;

ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; COST SAVINGS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION, RENAL; TETRAZOLES;

EID: 16644379512     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.09229.x     Document Type: Article

References (15)

1. LEA JP, NICHOLAS SB: Diabetes mellitus and hypertension: Key risk factors for kidney disease. J Natl Med Assoc 94(8 Suppl):7S-15S, 2002
2. U.S. RENAL DATA SYSTEM: USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001
3. VORA JP, IBRAHIM HA, BAKRIS GL: Responding to the challenge of diabetic nephropathy: The historic evolution of detection, prevention and management. J Hum Hypertens 14:667-685, 2000
4. MUNTNER P, CORESH J, POWE NR, KLAG MJ: The contribution of increased diabetes prevalence and improved myocardial infarction and stroke survival to the increase in treated end-stage renal disease. J Am Soc Nephrol 14:1568-1577, 2003
5. LORENZO V, MARTIN UB: Epidemiologic analysis of the increase in terminal renal insufficiency associated with type 2 diabetes mellitus. Nefrologia 20(Suppl 5):77-81, 2000
6. CARRETERO-DIOS D, PEREZ-GARCIA R, RODRIGUEZ-BENITEZ P, et al: Diabetes mellitus as cause of terminal renal failure. An epidemic of the 21st century? Nefrologia 21(Suppl 3):83-87, 2001
7. PARVING HH, LEHNERT H, BROCHNER-MORTENSEN J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:910-912, 2001
8. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
9. PALMER AJ, ANNEMANS L, ROZE S, et al: Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding angiotensin converting enzyme inhibitors, other angiotensin-2-receptor antagonists and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 27:1897-1903, 2004
10. PALMER AJ, ANNEMANS L, ROZE S, et al: Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. Kidney Int 2004
11. RODBY RA, CHIOU CF, BORENSTEIN J, et al: The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther 25:2103-2119, 2003
12. PALMER AJ, ANNEMANS L, ROZE S, et al: An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: Cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian, and French settings. Nephrol Dial Transplant 18:2059-2066, 2003
13. PALMER AJ, ANNEMANS L, ROZE S, et al: An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. J Hum Hypertens 2004 (Epub ahead of print)
14. PALMER AJ, ANNEMANS L, ROZE S, et al: Gesundheitsökonomische Aspekte der Anwendung von Irbesartan in Deutschland. Health economic consequences of irbesartan treatment of type 2 diabetes patients with hypertension and nephropathy in Germany. Dtsch Med Wochenschr 129:13-18, 2004
15. PALMER AJ, ANNEMANS L, ROZE S, et al: Cost-effectiveness of Irbesartan in patients with type 2 diabetes, hypertension and nephropathy: A Spanish perspective. Nefrologia 24:231-238, 2004